Teh BT - Search Results

1

Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.

Schaeffer EM, Guzzo TJ, Furge KA, Netto G, Westphal M, Dykema K, Yang X, Zhou M, Teh BT, Pavlovich CP. Schaeffer EM, et al. Among authors: teh bt. BJU Int. 2010 Jul;106(1):62-5. doi: 10.1111/j.1464-410X.2009.09139.x. Epub 2009 Dec 11. BJU Int. 2010. PMID: 20002663

2

Gene expression profiling of renal cell carcinoma.

Tan MH, Rogers CG, Cooper JT, Ditlev JA, Maatman TJ, Yang X, Furge KA, Teh BT. Tan MH, et al. Among authors: teh bt. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6315S-21S. doi: 10.1158/1078-0432.CCR-050002. Clin Cancer Res. 2004. PMID: 15448024 Review.

3

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R. Hammers HJ, et al. Among authors: teh bt. Mol Cancer Ther. 2010 Jun;9(6):1525-35. doi: 10.1158/1535-7163.MCT-09-1106. Epub 2010 May 25. Mol Cancer Ther. 2010. PMID: 20501804 Free PMC article.

4

Gene expression profiling of renal medullary carcinoma: potential clinical relevance.

Yang XJ, Sugimura J, Tretiakova MS, Furge K, Zagaja G, Sokoloff M, Pins M, Bergan R, Grignon DJ, Stadler WM, Vogelzang NJ, Teh BT. Yang XJ, et al. Among authors: teh bt. Cancer. 2004 Mar 1;100(5):976-85. doi: 10.1002/cncr.20049. Cancer. 2004. PMID: 14983493 Free article.

5

Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling.

Furge KA, Tan MH, Dykema K, Kort E, Stadler W, Yao X, Zhou M, Teh BT. Furge KA, et al. Among authors: teh bt. Oncogene. 2007 Feb 26;26(9):1346-50. doi: 10.1038/sj.onc.1210256. Oncogene. 2007. PMID: 17322920 Review.

6

Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma.

Furge KA, Dykema K, Petillo D, Westphal M, Zhang Z, Kort EJ, Teh BT. Furge KA, et al. Among authors: teh bt. Can Urol Assoc J. 2007 Jun;1(2 Suppl):S21-7. doi: 10.5489/cuaj.64. Can Urol Assoc J. 2007. PMID: 18542781 Free PMC article.

7

A molecular classification of papillary renal cell carcinoma.

Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. Yang XJ, et al. Among authors: teh bt, teh bs. Cancer Res. 2005 Jul 1;65(13):5628-37. doi: 10.1158/0008-5472.CAN-05-0533. Cancer Res. 2005. PMID: 15994935

8

MicroRNA profiling of human kidney cancer subtypes.

Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT. Petillo D, et al. Among authors: teh bt. Int J Oncol. 2009 Jul;35(1):109-14. doi: 10.3892/ijo_00000318. Int J Oncol. 2009. PMID: 19513557

9

Renal cell carcinoma deep sequencing: recent developments.

Farber LJ, Furge K, Teh BT. Farber LJ, et al. Among authors: teh bt. Curr Oncol Rep. 2012 Jun;14(3):240-8. doi: 10.1007/s11912-012-0230-3. Curr Oncol Rep. 2012. PMID: 22535504 Review.

10

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.

Furge KA, MacKeigan JP, Teh BT. Furge KA, et al. Among authors: teh bt. Lancet Oncol. 2010 Jun;11(6):571-8. doi: 10.1016/S1470-2045(09)70380-8. Epub 2010 Apr 8. Lancet Oncol. 2010. PMID: 20381423 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

504 results

Search Page

Filters